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Abstract
Background: A new locus for amyotrophic lateral sclerosis – frontotemporal dementia (ALS-FTD) has recently
been ascribed to chromosome 9p.
Methods: We identified chromosome 9p segregating haplotypes within two families with ALS-FTD (F476 and
F2) and undertook mutational screening of candidate genes within this locus.
Results: Candidate gene sequencing at this locus revealed the presence of a disease segregating stop mutation
(Q342X) in the intraflagellar transport 74 (IFT74) gene in family 476 (F476), but no mutation was detected within
IFT74 in family 2 (F2). While neither family was sufficiently informative to definitively implicate or exclude IFT74
mutations as a cause of chromosome 9-linked ALS-FTD, the nature of the mutation observed within F476
(predicted to truncate the protein by 258 amino acids) led us to sequence the open reading frame of this gene in
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a large number of ALS and FTD cases (n = 420). An additional sequence variant (G58D) was found in a case of
sporadic semantic dementia. I55L sequence variants were found in three other unrelated affected individuals, but
this was also found in a single individual among 800 Human Diversity Gene Panel samples.
Conclusion: Confirmation of the pathogenicity of IFT74 sequence variants will require screening of other
chromosome 9p-linked families.
Background
Amyotrophic lateral sclerosis (ALS, Online Mendelian
Inheritance in Man (OMIM) 105400) is characterized by
progressive motor neuron degeneration resulting in paral-
ysis and death, usually from respiratory failure, within 3
to 5 years of symptom onset[1]. ALS is typically sporadic
in nature. However, 5–10% of cases are familial, and the
identification of causal mutations has provided insight
into the disease processes that lead to neurodegeneration
[2-5]. Frontotemporal dementia (FTD, OMIM 600274) is
a degenerative disorder of the frontal and anterior tempo-
ral lobes [6] and is the second most common cause of
dementia accounting for approximately 20% of pre-senile
cases [7]. The syndrome is characterized clinically by ini-
tial behavioral and psychological disturbances, followed
by cognitive decline eventually leading to dementia and
death within a median of seven years from symptom
onset [8]. There is a family history of dementia in over
40% of FTD cases suggesting genetic components [8].
Clinical and pathological data indicate that ALS and FTD
can form a spectrum of disease [9]. Approximately 5% of
ALS patients have clinically florid dementia (ALS-FTD)
[10] and roughly half of patients with "classical" ALS have
subtle frontal and temporal lobe impairment [11]. Many
sporadic and familial FTD cases similarly develop clinical
symptoms of motor neuron involvement during the
course of their illness [12,8]. Furthermore, ubiquitin
inclusions and dystrophic neurites are the hallmark neu-
ropathological findings common to ALS without cogni-
tive impairment, ALS with cognitive impairment, ALS-
FTD and "pure" FTD with a greater distribution and load
of lesions being associated with cognitive impairment
[13].
Recently, linkage of ALS-FTD in Dutch and Scandinavian
families with apparently autosomal dominant disease was
ascribed to a 9.8 megabase (Mb) region at chromosome
9p13.2–21.3 [14,15]. This linkage was replicated and
additional haplotype information from seven American
ALS-FTD kindreds narrowed the 9p locus to a 2.1 Mb
region flanked by D9S1678 and D9S2154 containing 14
genes (figure 1) [16]. We identified two families from the
United States that were potentially linked to the 9p locus.
Using these families, we undertook a methodical assess-
ment of candidate genes in an attempt to identify the
underlying genetic lesion responsible for disease.
Methods
Subjects and samples
F476 was a four-generation, 15-member North American
ALS-FTD kindred. The proband (figure 2a, III-3) was a 58-
year-old male with a seven year history of behavioral FTD
symptoms who subsequently developed ALS during the
course of his illness. His younger brother (III-4) devel-
oped perseveration, lack of insight and dysregulation of
social and interpersonal conduct at the age of 52. He later
developed motor weakness and remains alive three years
after disease onset. An older brother (III-1) began show-
ing poor judgment and inappropriate behavior at 50 years
of age. He died twelve years later with severe dementia.
Marked frontal and anterior temporal lobe atrophy was
detected at post-mortem. Histology revealed the stereo-
typical features of frontotemporal lobar degenerations
(FTLDs): neuronal loss, microvacuolation, and gliosis
(figure 3). The frontal lobe was the most severely affected
region with focal trancortical neuronal loss. Ubiquitin
immunohistochemistry revealed neuronal cytoplasmic
inclusions, sparse neuronal intranuclear inclusions, and
dystrophic neurites identical to those seen in familial and
sporadic cases of FTLD with ubiquitin-positive, tau-nega-
tive inclusions (FTLD-U). There were Bunina bodies in the
motor neurons of the anterior horns of the cervical spinal
cord, but there was no evidence of corticospinal tract
degeneration seen in cases of motor neuron disease. This
case had additional Alzheimer's disease-type pathology,
namely diffuse beta-amyloid plaques in the absence of
neuritic plaques or neurofibrillary tangles. Autopsies and
neuropathological procedures were performed according
to the protocols of the Washington University Alzheimer's
Disease Research Center neuropathology Core.
F2 was a three-generation, 16-member North American
kindred, in which seven individuals had been diagnosed
with ALS-FTD (figure 2b).
Patients with ALS fulfilled the El Escorial criteria for prob-
able or definite ALS and were diagnosed by a consultant
neurologist after exclusion of ALS mimic syndromes [17].
Frontotemporal dementia was diagnosed by clinical and
neuropsychological criteria. The diagnosis was confirmed
by autopsy in one familial ALS-FTD case.BMC Neurology 2006, 6:44 http://www.biomedcentral.com/1471-2377/6/44
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Marker analysis
DNA was extracted by standard procedures after ethically
approved, written informed consent was obtained. Ethical
approval for collection of DNA and clinical phenotype
information was provided by the National Institute of
Aging Institutional Review Board, Baltimore, MD (proto-
col #2003-081). Polymerase chain reaction (PCR) was
performed to amplify DNA with markers spaced across
the known chromosome 9p21 locus. Markers were
selected from the Applied Biosystems Prism Linkage Map-
ping Set Version 2.5 (ABI, Foster City, CA). Additional
makers were chosen based on mapping information pub-
licly available from the UNISTS database at the National
Center for Biotechnology Information (NCBI). For allele
identification, the PCR products were separated and
scored using automated ABI 3100 sequencing equipment.
Sequencing of candidate genes
The 14 genes within the 2.1 Mb region of the 9p locus
defined by the Dutch, Scandinavian and North American
families[14-16] were identified from the NCBI [18] and
Ensembl databases [19]. Genomic primer design for all
genes was performed using ExonPrimer [20]. Each exon
and at least 30 bp of flanking intronic sequence was PCR
amplified using primer pairs (available upon request)
using whole genome amplified DNA (Repli-G, Qiagen
Inc., Valencia, CA) from affected individuals of each fam-
ily used. PCR amplification was carried out using Qiagen
HotStarTaq master mix polymerase, and 10 pmol of both
forward and reverse primers per the manufacturer's
instructions (Qiagen Inc.). Each product was sequenced
using forward and reverse primers with Applied Biosys-
tems BigDye terminator v3.1 sequencing chemistry as per
the manufacturer's directions. The resulting reactions
Ideogram of the Chromosome 9p ALS-FTD locus Figure 1
Ideogram of the Chromosome 9p ALS-FTD locus. (A) ideogram of chromosome 9 showing the linked areas defined by Morita 
et al, Vance et al and Yan et al in 2006. The shared region flanked by D9S1678 and D9S2154 is shaded in grey. (B) Schematic 
representation of the known genes and predicted transcripts in the area shared by the Dutch, Scandinavian and North Ameri-
can families. In red, IFT74 where sequence variants associated with ALS-FTD, ALS and FTD were identified.
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were run on an ABI3100 genetic analyzer and analyzed
with Sequencher software (version 4.5, GeneCodes Corp.,
MI). Detected sequence variants were confirmed by repeat
PCR amplification and sequencing using original
genomic DNA. In addition to these 14 genes, we also
sequenced an additional 47 genes in the larger haplotype
before the report [16] limiting the linked haplotype
became public (Table 1, primers available upon request).
Coding and flanking regions of Cu/Zn superoxide dis-
mutase (SOD1), microtubule associated protein tau
(MAPT) and progranulin (GRN) genes known to be asso-
ciated with ALS-FTD[21-24], had been sequenced for
mutations as previously described[25,22].
Mutation assay
The presence of IFT74 sequence variants were assessed in
500 North American control subjects, 9 ALS-FTD cases
with a positive family history of ALS-FTD, 11 cases of ALS-
FTD without a family history, 164 sporadic FTD cases, 31
cases of familial FTD, 127 Irish cases of ALS and 83 North
American cases of ALS (see Table 2 for list of samples). In
addition, we used 800 DNA samples from the Centre
d'Etude du Polymorphisme Humain (CEPH) Human
Genome Diversity Panel (HGDP), a resource of individu-
als from 51 different world populations. Information for
this panel is limited to sex of the individual and popula-
tion origin [26]. To identify the Q342X sequence variant,
a genomic fragment was amplified using the primer pair
5'-TGGAAAAGATATCTAACCTCCCC-3' and 5'-CCCAGG-
TAGTTGAACAGTCTCTG-3'. The resulting 262 bp frag-
ment was sequenced as described above. The remaining
18 exons of IFT74 were also amplified and sequenced in
the patient samples to determine the presence of sequence
Pedigrees showing affection status, individual IDs, and haplotypes for (a) family 476 and (b) family 2 Figure 2
Pedigrees showing affection status, individual IDs, and haplotypes for (a) family 476 and (b) family 2. Gender has been masked 
to protect the anonymity of the families. Probands are indicated by arrows; open symbol, unaffected; shaded symbol, affected; 
diagonal line, deceased; current age, or age at death and cause of death, is indicated. AD, Alzheimer Disease. Brackets around 
an allele indicate an inferred haplotype. Arrows show the limits of the haplotype.
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variants in the rest of the gene (see table 3 for list of prim-
ers).
cDNA amplification
cDNA from a marathon Rapid Amplification of cDNA
Ends (RACE)-ready adult human brain library (BD Bio-
sciences, CA) was used as a template to amplify overlap-
ping fragments of the predicted 2 kilobase (kb) transcript.
Overlapping primers within each exon were designed
using ExonPrimer, and PCR and sequencing were carried
out as described above.
Western blotting
Human brain soluble extracts (40 ug per lane) were sepa-
rated on 4–20% sodium dodecyl sulphate – polyacryla-
mide gel electrophoresis (SDS-PAGE) gels and blotted
using a goat polyclonal antibody to the C-terminus of
IFT74 (anti-CMG1, Everest Biotech Ltd, Oxfordshire, UK)
at a final antibody concentration of 0.5 ug mL-1. For com-
petition experiments, antibody was pre-incubated with a
10-fold excess (w/w) of immunizing peptide (KTIVDALH-
STSGN).
Confocal microscopy
Primary cortical neurons were prepared from E18 rat pups
using papain dissociation and were plated on poly-L-
lysine coated glass coverslips at 106 cells per dish. After 5
days in vitro, cells were fixed with 4% paraformaldehyde,
permeabilized with 0.1% saponin and stained with the
goat polyclonal antibody to IFT74 at a concentration of
2.5 mg mL-1. Secondary antibody was donkey anti-goat
IgG conjugated to AlexaFluor 488 (1:200, Molecular
Probes, Carlsbad, CA) and nuclei were identified with TO-
PRO3 (Molecular probes). Coverslips were imaged with a
Zeiss LSM510 META confocal microscope using consist-
ent gain and offset settings for samples stained with anti-
body alone or with antibody plus immunizing peptide.
Secondary antibody alone gave no signal.
Results
Previous linkage analysis of F2 using dinucleotide marker
data had revealed a single region with a lod score of ~1.5
on chromosome 9p that matched with the published
chromosome 9p21.3-p13.3 ALS-FTD locus (figure 2b).
Similarly, marker data showed a haplotype across chro-
mosome 9p that segregated with disease status in F476
(figure 2a). Based on these data, F476 and F2 were
selected for mutational screening of the 14 candidate
genes within the previously defined 2.1 Mb region of the
chromosome 9p ALS-FTD locus.
In the course of sequencing the intraflagellar transport
gene (IFT74), we identified a C to T sequence variant at
nucleotide 1024 in exon 13 in the proband of F476 (III-3,
figures 4a and 5). This base pair change predicts a prema-
(A) On the left, hemi-brain from individual III-1 of family 476  diagnosed with FTD showing marked frontal and anterior  temporal lobe atrophy Figure 3
(A) On the left, hemi-brain from individual III-1 of family 476 
diagnosed with FTD showing marked frontal and anterior 
temporal lobe atrophy. On the right, a coronal slice showing 
severely dilated lateral ventricles with narrowed gyri and 
widened sulci; (B) ubiquitin-positive, tau-negative inclusions 
in the superficial laminae of the middle frontal gyrus (arrow, 
scale bar = 10 nm); (C) high power photomicrograph of a 
neuronal cytoplasmic inclusion; (D) high power photomicro-
graph of a dystrophic neurite in the neuropil; (E) high power 
photomicrograph of a neuronal intranuclear inclusion (C -E, 
bar = 5 nm); (F) Ubiquitin-positive cytoplasmic inclusions in 
motor neurons of the lower medulla-spinal cord (arrow, bar 
= 50 nm); (G) higher power photomicrograph of a neuron 
containing a cluster of Bunina body-like inclusions; (H) higher 
power photomicrograph of a loosely aggregated cytoplasmic 
inclusion (G & H, ubiquitin immunohistocemistry, bar = 5 
nm).BMC Neurology 2006, 6:44 http://www.biomedcentral.com/1471-2377/6/44
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ture stop codon at position 342 of the peptide (Q342X)
truncating the last 258 residues. This variant segregated
with disease within the family as it was present in the two
brothers of the proband diagnosed with ALS-FTD (III-1,
III-4). The Q342X sequence variant was not present in
four unaffected individuals within the kindred (II-3, III-2,
IV-2 & IV-4), in 1,000 chromosomes from North Ameri-
can controls or in 900 chromosomes from the Human
Genome Diversity Panel although this C to T base pair
change is ostensibly in a library clone derived from
human thymus (BX436367, clone CS0CAP001YM04, Life
Technologies, Inc). One younger unaffected individual
carried the Q342X sequence variant. We did not find
IFT74 sequence variants in F2 by sequencing or exonic
gene dosage methods (data not shown). Neither F476 or
F2 had additional mutations in the other 13 genes within
the 9p locus defined by the Dutch, Scandinavian and
North American families[14-16] or in 47 additional genes
in the larger haplotype.
In order to assess the prevalence of IFT74 sequence vari-
ants, we sequenced the entire coding region of this gene in
a large number of ALS, ALS-FTD and FTD samples (Table
2). The Q342X mutation was not found in any of these
patients. However, we identified a G58D (nt173 G to A)
sequence variant in a Caucasian woman who developed
sporadic semantic dementia without motor involvement
at the age of 58 (II-1, figures 4b and 5). This G58D
sequence variant was not found in 900 chromosomes
from North American controls or in 1,600 chromosomes
from the HGDP. We also identified an I55L sequence var-
iant (nt163 A to T) in three additional affected probands;
first, the I55L sequence variant was found in the proband
of F549 who had been diagnosed with FTD at the age of
62 (figures 4c and 5). His 80-year-old brother (II-7) had
been diagnosed with FTD at the age of 75 and carried the
I55L sequence variant. A 70-year-old apparently unaf-
fected sister (II-12) also carried the I55L sequence variant;
second, the proband of F194, a 59-year-old Caucasian
woman diagnosed with ALS-FTD, had the I55L sequence
variant. Her sister had died of FTD and her paternal uncle
had died of ALS-FTD (DNA samples not available); third,
the I55L sequence variant was found in a 67-year-old man
with sporadic ALS. He had presented one year before his
death with bulbar symptoms including emotional labil-
ity, and had become increasingly withdrawn and indiffer-
ent to his symptoms during the course of his illness. I55L
was not found in 900 chromosomes from North Ameri-
can controls, but it was found in 1 of 1,600 chromosomes
from the HGDP in a French sample.
We proceeded to verify that IFT74 is expressed in brain.
Refseq (NCBI) provisionally reports the IFT74  gene to
contain 14 coding exons based on NM_025103. We
sequenced human brain derived cDNA and found a T to A
transversion at nt599 of NM_025103 (primers available
Table 1: Genes in the extended Chromosome 9p ALS-FTD locus* that were excluded as candidate genes by sequencing
Start bp Symbol Start bp Symbol
26,056,673 LOC441390 33,245,026 BAG1
29,814,856 LOC286239 33,255,000 C9orf83
30,378,933 LOC401497 33,278,862 LOC441393
30,678,956 LOC441391 33,280,510 NFX1
30,679,911 LOC442405 33,374,948 AQP7
30,789,463 LOC442406 33,431,162 AQP3
30,811,997 LOC441392 33,451,352 NOL6
31,243,899 LOC138412 33,493,783 LOC441394
32,323,455 LOC392301 33,514,488 ANKRD18B
32,374,650 ACO1 33,570,693 LOC441395
32,445,705 DDX58 33,607,843 TRBV20OR9-2
32,530,543 TOPORS 33,614,223 ANXA2P2
32,543,523 NDUFB6 33,619,141 TRBV21OR9-2
32,619,452 TAF1L 33,623,851 TRBV22OR9-2
32,633,108 LOC389710 33,628,035 TRBV23OR9-2
32,773,497 LOC401498 33,639,129 TRBV24OR9-2
32,935,943 LOC392302 33,652,201 TRBV25OR9-2
32,962,608 APTX 33,665,438 PTENP1
33,009,952 LOC401499 33,672,268 TRBVAOR9-2
33,015,309 DNAJA1 33,685,578 TRBV26OR9-2
33,031,762 LOC401500 33,776,219 TRBV29OR9-2
33,037,169 SMU1 33,785,559 PRSS3
33,100,642 B4GALT1 33,807,565 UBE2R2
33,230,196 SPINK4
*as defined by the Dutch and Scandinavian families [14,15]BMC Neurology 2006, 6:44 http://www.biomedcentral.com/1471-2377/6/44
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upon request). This base pair substitution converts a stop
codon at position 159 to lysine indicating that IFT74 con-
tains 19 exons encoding a 600 residue protein with a pre-
dicted molecular weight of 69.2 kDa. This larger coding
region of IFT74 was confirmed by deposited sequences
AY040325 and CR617782, which show lysine at codon
position 159. Western blotting of human brain lysates
with a polyclonal antibody against a peptide from the C-
terminus of IFT74 demonstrated two major bands at ~90
kDa and ~70 kDa, of which the lower band is the most
prominent (figure 6a). Both of these bands were blocked
by pre-absorption of the antibody with the immunizing
peptide (data not shown), indicating specificity. These
data show that this gene is expressed throughout the adult
human brain and also confirmed that IFT74 contains 19
exons. Staining of primary rat cortical neurons with the
same antibody demonstrated that IFT74 is localized to
vesicles in the cell body and along the neuronal processes
(figure 6b).
Discussion
We found sequence variations in the IFT74  gene in
patients with ALS-FTD, FTD and sporadic ALS. Five pieces
of genetic information suggest that the IFT74 sequence
variants are relevant to disease pathogenesis. First, the
nonsense sequence variant (Q342X) segregates with dis-
ease in a small ALS-FTD kindred. Second, this premature
stop codon significantly truncates the IFT74 protein in a
manner likely to have a critical effect on the function of
this plausible candidate gene. Third, additional sequence
variants (G58D and I55L) were found in the IFT74 gene
in other disease cases. Fourth, we have sequenced every
known gene and predicted transcripts in the candidate
region as defined by the minimal interfamily haplotype
shared by the Dutch, Scandinavian and North American
ALS-FTD families (figure 1) and the gene encoding IFT74
was the only gene that contained variants not identified in
the general population and fifth, these mutations are not
present in 900 to 1,000 North American control chromo-
somes.
Against these five pieces of suggestive information are four
pieces of evidence against pathogenicity. First, we failed to
find a mutation in the second family we used in our
screening (F2). Second, the fact that the stop mutation is
in the cDNA database in a sample of unknown prove-
nance, third the fact that the I55L mutation is in a sample
from France in the CEPH diversity series argues against the
pathogenicity of that particular mutation. The genetic
linkage reports indicate that mutations at the chromo-
some 9p locus are incompletely penetrant [14,15] and
this complicates the interpretation of both segregation
data within families and of variants in control popula-
tions. Fourth: on contacting the senior authors of the orig-
inal linkage report [14], they were unable to find a point
variant in their linked family.
Conclusion
Our data indicate that IFT74 is a 600-residue, 69-kDa
coiled-coil containing protein that localizes to the intrac-
ellular vesicle compartment. This protein is a component
of the intraflagellar transport system responsible for vesic-
ular transport of material synthesized within the cell body
into and along the dendritic and axonal processes of
human neurons[27]. The importance of vesicle synthesis
and axonal transport in motor neuron disease is increas-
ingly recognized. Vesicle associated protein B missense
(VAPB) mutations have been identified in familial ALS [5]
and the wobbler mouse, an animal model of ALS, is
caused by mutations in the vesicular protein sorting factor
54 [28]. Dynactin is the motor protein responsible for ret-
rograde axonal transport and mutations in the p150 sub-
unit of this complex have been described in patients with
ALS [29] and ALS-FTD [30]. Furthermore, a mutation in
the antegrade axonal transport kinesin gene, KIF1B, has
been described in a single family with Charcot-Marie-
Tooth disease-2A1, a hereditary motor and sensory axonal
neuropathy (OMIM 118210). Given its role in vesicle
transport, IFT74 is a plausible biological candidate to
explain the neurodegeneration characteristic of both ALS
and FTD phenotypes in a subset of patients. However, as
Table 2: Samples in which the IFT74 gene was sequenced
Whole gene Exon 2 Exon 12
NINDS ALS-FTD and FTD samples [32] 32
Toronto ALS-FTD and FTD samples [33] 95
Irish ALS-FTD and ALS samples [34] 127
Johns Hopkins ALS samples 51
New York Brain Bank ALS, ALS-FTD and FTD samples 24
University of Miami/National Parkinson Foundation ALS samples 7
Miscellaneous ALS, ALS-FTD and FTD samples 84
North American control samples* 450 500
Human Genome Diversity panel [26] 800 450
Total 420 1,250 950
*available from the NINDS Neurogenetics Repository at the Coriell Institute for Medical Research, Camden, NJBMC Neurology 2006, 6:44 http://www.biomedcentral.com/1471-2377/6/44
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the Q342X mutation was found in a cDNA library and in
an (as yet) unaffected family member, there is currently
no clear evidence that this mutation is of causal signifi-
cance and IFT74 may just be a risk factor for ALS-FTD.
Clearly, more work will be needed to determine its role, if
any.
Accession numbers
Intraflagellar transport 74 homolog (IFT74, also known as
capillary morphogenesis protein 1 (CMG1); coiled-coil
domain containing 2 (CCDC2); FLJ22621): GeneID
80173; UniGene Hs.145402; mRNA: AY040325
(gi:15418996); protein: AAK77221 (GI:15418997);
SOD1  (NM_000454);  MAPT  (NM_016835);  GRN
(NM_002087).
Online Mendelian inheritance in man [31]
Amyotrophic lateral sclerosis [ALS, OMIM 105400];
Fronto-temporal dementia [FTD, OMIM 600274]; Fronto-
temporal dementia/amyotrophic lateral sclerosis [ALS/
FTD, OMIM 105550], Intraflagellar transport protein 74
(IFT74), previously CCDC2, CMG1 [OMIM 608040]
Abbreviations
ALS, amyotrophic lateral sclerosis; FTD, frontotemporal
dementia, IFT74, intraflagellar transport 74 homologue;
OMIM, online Mendelian inheritance in man; FTLD, fron-
totemporal lobar degeneration; FTLD-U, FTLD with ubiq-
uitin-positive, tau-negative inclusions; MND, motor
neuron disease; NCBI, national center for biotechnology
information; SOD1, superoxide dismutase one; MAPT,
Table 3: Primers used to sequence the 19 exons of IFT74
Sequence Product size
Exon 1 Forward TGAACAAAATTAGCCTTGTAGTGG 395
Exon 1 Reverse AAAAACTGGGGTGCAGTGG
Exon 2 Forward CTTTGCAGTTTTACAATAAAAGATGT 400
Exon 2 Reverse CCATAATTCTGATTACATGCCATA
Exon 3 Forward TTGGATTTGCTATTCTGGTGG 172
Exon 3 Reverse GACAGAAGGTACACAATATTTCGAG
Exon 4 Forward AATTTTGCTTAACTAGAGTTTTCTGG 250
Exon 4 Reverse TGAACATTACAAACAATATGGATAGC
Exon 5 Forward TTGTAGCTATCCATATTGTTTGTAATG 282
Exon 5 Reverse CTTGTTGGCTGCATGTTTG
Exon 6 Forward TTTGTTTGTATTTTTGTTTTTAGTTGG 246
Exon 6 Reverse GCAACTAAGGGAGCTCAAGG
Exon 7 Forward TCATTTAGTTCCTAGCCAAAATAACC 230
Exon 7 Reverse CAAGGAAATAACTGGATCACAAC
Exon 8 Forward AGTCACACACTGTGGTTGAATG 343
Exon 8 Reverse TGCTGATGCTGCTGATATTC
Exon 9 Forward TTTCCCAGCTCCCTCCC 304
Exon 9 Reverse CTAGGATCTTTGTGGGTCCAG
Exon 10 Forward CCCCATTCTTATAAACTGAAACC 324
Exon 10 Reverse AGCTTTACTACTTGCATTAATATCCC
Exon 11 Forward TTCAAGAAAGAGAGTAGATTTGACAC 301
Exon 11 Reverse TGCAATGGCTCTTAAACACTC
Exon 12 Forward TGGAAAAGATATCTAACCTCCCC 262
Exon 12 Reverse CCCAGGTAGTTGAACAGTCTCTG
Exon 13 Forward TGACTAATGGCATAGAGAGAACC 240
Exon 13 Reverse TATCTGCCCAAAATGAGGTC
Exon 14 Forward GCCTGGCAACAGAGTGAG 357
Exon 14 Reverse AAGGGAATTGAAAGGAAGCAG
Exon 15 Forward CATCCTTTGACAGTGTTTTCC 297
Exon 15 Reverse CAATGAGGCTTTAAAATAATCAGAG
Exon 16 Forward GAAATTGGTTATTGAGGGGATG 539
Exon 16 Reverse TTGCTTTTCTTTAAAACTTTAAGTCAC
Exon 17 Forward CGGGTTTTAGAGTAGTTATAGCCTTG 381
Exon 17 Reverse TGGCTGTCTTAAAAGTCAGAAAATC
Exon 18 Forward TTTTGTCTTATCCTCTTAGAAAGGC 259
Exon 18 Reverse TAGCCAGGGTGGTCTCAATC
Exon 19 Forward TGCTTAATCTGTTAAAATGATGTACTG 383
Exon 19 Reverse AATTTTAGGTAAACTCCAAAAGTAAGCBMC Neurology 2006, 6:44 http://www.biomedcentral.com/1471-2377/6/44
Page 9 of 11
(page number not for citation purposes)
Sequence variants in IFT74 are linked to Chromosome 9p ALS-FTD Figure 5
Sequence variants in IFT74 are linked to Chromosome 9p ALS-FTD. (A) Schematic of IFT74's structure. (B) Sequence variants 
I55L, G58D and Q342X are shown relative to affected protein domains and are indicated by black arrowheads. Human IFT74 
protein aligned with other orthologs from chimpanzee (XP_520518.1), dog (XP_531964.1), mouse (AAH23760.1) and rat 
(NP_001007002.1). Amino acid number is based on the human protein. (C) chromatograms showing wild type (top), forward 
mutant (middle) and reverse mutant (bottom) sequences of I55L (left), G58D (middle) and Q342X (right).
↓ ↓ ↓
Human MPPGTARPGSRGCPIGTGGVLSSQIKVAHRP----EKINQFIEEIRQLDMDLEEHQGEMNQKYKE
Chimp MPPGTARPGSRGCPIGTGGVLSSQIKVAHRP----EKKNQFIEEIRQLDMDLEEHQGEMNQKYKE
Dog LPPGTARPGSRGGPIGTGGVLSSQIKVADRP----EKINQFSEEIRQLDMDLEEHQGEMNQKYKE
Mouse MPPTTARPGSRGGPLGTGGVLSSQIKVADRP----EKINQFSEEIRQLDMDLEEHQGEMNQKYKE
Rat MPPATARPGSRGGPLGTGGVLSSQIKVADRP----EKINQFSEEIRQLDMDLEEHQGEMNQKYKE
Coiled-coil domain
B
A
C
1 600
41 71 331 360
ATA → TTA (I55L) GGT → GAA (G58D) CAA → TAA (Q342X)
Family 476, 95, 549 and 13 originate from North America Figure 4
Family 476, 95, 549 and 13 originate from North America. WT indicates a mutation-negative subject, Q342X, G58D and I55L 
indicate subjects carrying a heterozygous sequence variation. Currently unaffected mutation carriers have not been shown; in 
all instances these individuals have not yet reached the maximum age at onset observed.
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microtubule-associated protein tau; GRN, granulin;
CEPH, Centre d'Etude du Polymorphisme Humain;
HGDP, Human Genome Diversity Panel; cDNA, comple-
mentary DNA; RACE, Rapid Amplification of cDNA Ends;
SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel
electrophoresis; CMG1, capillary morphogenesis protein
1; Refseq, reference sequence; KIF1B, kinesin family mem-
ber 1B.
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